Physician profile
Dene' Beck
NPI 1619513819
$2,394.60
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,307 · 2022: $1,088.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $350.58 | 2021-2022 | |
| Incyte Corporation | $243.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $225.08 | 2021-2022 | |
| Janssen Biotech, INC. | $199.12 | 2021-2022 | |
| Lilly USA, LLC | $171.01 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.52 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $126.92 | 2021-2022 | |
| Seagen INC. | $125.33 | 2021 | |
| Abbvie INC. | $116.72 | 2021 | |
| Celgene Corporation | $92.59 | 2021-2022 | |
| Genentech USA, INC. | $80.13 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $62.07 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $57.87 | 2021-2022 | |
| Genzyme Corporation | $56.98 | 2021 | |
| Eisai INC. | $44.35 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $44.27 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.41 | 2022 | |
| Pfizer INC. | $26.99 | 2022 | |
| Astellas Pharma US INC | $24.93 | 2022 | |
| Merck Sharp & Dohme LLC | $23.83 | 2021 | |
| Taiho Oncology, INC. | $23.28 | 2021 | |
| Daiichi Sankyo INC. | $21.35 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.36 | 2021 | |
| Servier Pharmaceuticals LLC | $15.90 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.78 | 2022 | |
| Pharmaessentia USA Corporation | $12.86 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dene' Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.